Adora2a inhibition as a novel therapeutic target for cisplatin chemobrain-induced cognitive dysfunction

被引：0
|
作者：
Oliveros, Alfredo [1 ]
Yoo, Ki-Hyun [1 ]
Tang, Jun [1 ]
Corujo, Ana M. [1 ]
Brogren, Danielle [1 ]
Liu, Yuanhang [1 ]
Jang, Mi-Hyeon [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-4141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4141
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Adora2a inhibition via caffeine as a novel therapeutic target for cisplatin-induced chemobrain.
    Oliveros, Alfredo
    Corujo-Ramirez, Ana M.
    Yoo, Ki-Hyun
    Tang, Jason
    Brogren, Danielle
    Rashid, Mohammad A.
    Liu, Yuanhang
    Jang, Mi-Hyeon
    CANCER RESEARCH, 2021, 81 (13)
  • [2] A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction
    Gile, Jennifer
    Oyama, Yoshimasa
    Shuff, Sydney
    Eckle, Tobias
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (34) : 4330 - 4337
  • [3] Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction
    Bao, Yongjie
    Rong, Wenni
    Zhu, An
    Chen, Yuan
    Chen, Huiyue
    Hong, Yirui
    Le, Jingyang
    Wang, Qiyao
    Naman, C. Benjamin
    Xu, Zhipeng
    Liu, Lin
    Cui, Wei
    Wu, Xiang
    PHARMACEUTICS, 2023, 15 (09)
  • [4] Endothelial Adora2a Activation Promotes Blood-Brain Barrier Breakdown and Cognitive Impairment in Mice with Diet-Induced Insulin Resistance
    Yamamoto, Masaki
    Guo, De-Huang
    Hernandez, Caterina M.
    Stranahan, Alexis M.
    JOURNAL OF NEUROSCIENCE, 2019, 39 (21): : 4179 - 4192
  • [5] HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1
    Omrani, A.
    van der Vaart, T.
    Mientjes, E.
    van Woerden, G. M.
    Hojjati, M. R.
    Li, K. W.
    Gutmann, D. H.
    Levelt, C. N.
    Smit, A. B.
    Silva, A. J.
    Kushner, S. A.
    Elgersma, Y.
    MOLECULAR PSYCHIATRY, 2015, 20 (11) : 1311 - 1321
  • [6] HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1
    A Omrani
    T van der Vaart
    E Mientjes
    G M van Woerden
    M R Hojjati
    K W Li
    D H Gutmann
    C N Levelt
    A B Smit
    A J Silva
    S A Kushner
    Y Elgersma
    Molecular Psychiatry, 2015, 20 : 1311 - 1321
  • [7] Novel therapeutic approach to target endothelial dysfunction in type 2 diabetes
    Sena, C. M.
    Pereira, A. M.
    Fernandes, R.
    Santos-Silva, D.
    Faustino, A.
    Ceica, R.
    CARDIOVASCULAR RESEARCH, 2014, 103
  • [8] Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease
    Sheng, Jianwen
    Zhang, Shanjin
    Wu, Lule
    Kumar, Gajendra
    Liao, Yuanhang
    Pratap, G. K.
    Fan, Huizhen
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [9] ZBTB2 is a novel therapeutic target for cisplatin-resistance in metastatic breast cancer
    Shin, V.
    Siu, M. T.
    Cheuk, I.
    Ho, J.
    Chen, J.
    Kwong, A.
    CANCER RESEARCH, 2017, 77
  • [10] Rip2: a novel therapeutic target for bacteria-induced inflammation?
    Jeyaseelan, S
    TRENDS IN MICROBIOLOGY, 2002, 10 (08) : 356 - 356
12345